Status:

COMPLETED

Study of Immune Cell Changes in the Genital Tract 2 Months After Initiation of an IUD for Contraception

Lead Sponsor:

Sharon Achilles

Conditions:

Genital Tract Mucosal Immunity

Genital Tract Microflora

Eligibility:

FEMALE

18-40 years

Phase:

NA

Brief Summary

This pilot study is being performed to investigate the influence that starting contraception with an IUD has on the local immune cell populations and features, with a particular focus on the cells and...

Eligibility Criteria

Inclusion

  • Non-pregnant, healthy females who are seeking an IUD for contraception
  • Age 18-40 years, inclusive at the time of enrollment
  • History of regular menstrual cycles defined as occurring every 21-35 days when not using hormones and with a variation of typical cycle length of no more than 5 days
  • Willing and able to sign the informed consent and to comply with the study protocol
  • Inclusion criteria for healthy control subjects:
  • Non-pregnant, healthy females
  • Age 18-40 years, inclusive at the time of enrollment
  • History of regular menstrual cycles defined as occurring every 21-35 days when not using hormones and with a variation of typical cycle length of no more than 5 days
  • Willing and able to sign the informed consent and to comply with the study protocol
  • Prior surgical sterilization or heterosexually abstinent

Exclusion

  • Use of any hormonal or intrauterine contraceptive method within the past two months
  • Use of DMPA within the past 10 months
  • Any of the following within the past two months:
  • Pregnancy or breastfeeding
  • Surgery/biopsy of the vulva, vagina, or cervix
  • History of STI
  • New sexual partner
  • Evidence of vaginal/pelvic infection on screening
  • Abnormal wet mount (see description above)
  • Pelvic exam findings clinically consistent with infection
  • Positive screen for Gc, Ct, or HIV (will be excluded post randomization)
  • Active HSV/ulcerative disease in the genital tract or perineum
  • History of immunosuppression (diabetes, HIV, chronic steroid use)
  • Use of vaginal product (N9, microbicide, douche, antifungal, steroid, or hormone) within the past 30 days
  • Use of any systemic or vaginal steroid or antibiotic within the past 30 days
  • Vaginal or anal intercourse within 1 week of sample collection
  • Heterosexual vaginal intercourse since last menses without condom use
  • History of hysterectomy
  • History of malignancy in the uterus or cervix
  • Uterine anomaly (bicornuate uterus, uterine septum, or uterine didelphys)
  • Allergy to copper and/or intolerance to levonorgestrel

Key Trial Info

Start Date :

November 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2011

Estimated Enrollment :

42 Patients enrolled

Trial Details

Trial ID

NCT01240811

Start Date

November 1 2010

End Date

November 1 2011

Last Update

December 26 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15213